Browse > Article

Hepatic Angiomyolipoma: Dual-Contrast MRI Findings Using Superparamagnetic Iron Oxide (SPIO) and Gadolinium Agents  

Kim, Min-Uk (Department of Radiology, Seoul National University Hospital)
Kim, Se-Hyung (Department of Radiology, Seoul National University Hospital)
Kim, Hyo-Cheol (Department of Radiology, Seoul National University Hospital)
Lee, Jae-Young (Department of Radiology, Seoul National University Hospital)
Kim, Min-A (Department of Pathology, Seoul National University Hospital)
Han, Joon-Koo (Department of Radiology, Seoul National University Hospital)
Choi, Byung-Ihn (Department of Radiology, Seoul National University Hospital)
Publication Information
Journal of the Korean Society of Radiology / v.63, no.6, 2010 , pp. 537-546 More about this Journal
Abstract
Purpose: To analyze imaging findings of hepatic angiomyolipomas (AMLs) on dualcontrast MRI using superparamagnetic iron oxide (SPIO) and gadolinium (Gd) agents. Materials and Methods: Five histopathologically-proven hepatic AMLs were enrolled in this study. Patients underwent dual-contrast MRI using SPIO and Gd agents on a 3.0T unit and performed a qualitative analysis consisting of measuring the signal intensity (SI) of the lesion, presence of fat, hemorrhage, early draining vein, tortuous tumoral vessels, as well as capsule and enhancement patterns. The signal drop of the lesion on post-SPIO images was also assessed. For the quantitative analysis, relative signal decrease (RSD, %) was calculated. Results: The presence of fat was noted in three lesions. An early draining vein and prominent tortous tumoral vessels were depicted in four lesions. No lesion was found to have a capsule. Four lesions showed early wash-in and early wash-out enhancement patterns, while the remaining lesion depicted strong and persistent enhancement. On post-SPIO images, signal drop was noted in the two lesions with no fat within the lesion. Their RSD was 21.1% and 38.0%, respectively. Conclusion: The presence of an early draining vein and tortuous tumoral vessels are characteristic dynamic enhanced MRI features of hepatic AMLs. In fat-deficient hepatic AMLs, the combination of dynamic enhanced MRI and SPIO-enhanced MRI might findings might increase the accuracy of making a correct diagnosis.
Keywords
Angiomyolipoma; Liver; Dual contrast Magnetic Resonance Imaging; Superparamagnetic Iron Oxide;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ahmadi T, Itai Y, Takahashi M, Onaya H, Kobayashi T, Tanaka YO, et al. Angiomyolipoma of the liver: significance of CT and MR dynamic study. Abdom Imaging 1998;23:520-526   DOI   ScienceOn
2 Reimer P, Rummeny EJ, Daldrup HE, Hesse T, Balzer T, Tombach B, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997;7:275-280   DOI   ScienceOn
3 Tsui WM, Colombari R, Portmann BC, Bonetti F, Thung SN, Ferrell LD, et al. Hepatic angiomyolipoma. A clinicopathological study of 30 cases and delineation of unusual morphological variants. Am J Surg Pathol 1999;23:34-48   DOI   ScienceOn
4 Zheng RQ, Kudo M. Hepatic angiomyolipoma: identification of an efferent vessel to be hepatic vein by contrast-enhanced harmonic ultrasound. Br J Radiol 2005;78:956-960   DOI   ScienceOn
5 Namkung S, Zech CJ, Helmberger T, Reiser MF, Schoenberg SO. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007;25:755-765   DOI   ScienceOn
6 Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183:59-64
7 Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792
8 van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999;290:153-157
9 Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al. Improved detection of focal liver lesions at MR imaging: a multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230:266-275   DOI   ScienceOn
10 Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200: 59-67   DOI
11 Prasad SR, Wang H, Rosas H, Menias CO, Narra VR, Middleton WD, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. Radiographics 2005;25:321-331   DOI   ScienceOn
12 Zhong DR, Ji XL. Hepatic angiomyolipoma-misdiagnosis as hepatocellular carcinoma: a report of 14 cases. World J Gastroenterol 2000;6:608-612
13 Ren N, Qin LX, Tang ZY, Wu ZQ, Fan J. Diagnosis and treatment of hepatic angiomyolipoma in 26 cases. World J Gastroenterol 2003;9:1856-1858   DOI
14 Kudo M, Okuno T, Tomita S, Kajiwara T, Shirane H, Usuki N, et al. Hepatic angiomyolipoma pre-operatively diagnosed by imaging. J Gastroenterol Hepatol 1993;8:483-488   DOI   ScienceOn
15 Clement O, Siauve N, Cuenod CA, Frija G. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Topics Magn Reson Imaging 1995;9:167-182
16 Soyer P, Dufresne AC, Somveille E, Scherrer A. Hepatic cavernous hemangioma: appearance on T2-weighted fast spin-echo MR imaging with and without fat suppression. AJR Am J Roentgenol 1997;168:461-465   DOI   ScienceOn
17 Montet X, Lazeyras F, Howarth N, Mentha G, Rubbia-Brandt L, Becker CD, et al. Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom Imaging 2004;29:60-70
18 Yoshimura H, Murakami T, Kim T, Nakamura H, Hirabuki N, Sakon M, et al. Angiomyolipoma of the liver with least amount of fat component: imaging features of CT, MR, and angiography. Abdom Imaging 2002;27:184-187   DOI   ScienceOn
19 Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991;22:233-237   DOI   ScienceOn
20 Yan F, Zeng M, Zhou K, Shi W, Zheng W, Da R, et al. Hepatic angiomyolipoma: various appearances on two-phase contrast scanning of spiral CT. Eur J Radiol 2002;41:12-18   DOI   ScienceOn
21 Takayama Y, Moriura S, Nagata J, Hirano A, Ishiguro S, Tabata T, et al. Hepatic angiomyolipoma: radiologic and histopathologic correlation. Abdom Imaging 2002;27:180-183   DOI   ScienceOn
22 Sakamoto Y, Inoue K, Ohtomo K, Mori M, Makuuchi M. Magnetic resonance imaging of an angiomyolipoma of the liver. Abdom Imaging 1998;23:158-160   DOI   ScienceOn
23 Basaran C, Karcaaltincaba M, Akata D, Karabulut N, Akinci D, Ozmen M, et al. Fat-containing lesions of the liver: cross-sectional imaging findings with emphasis on MRI. AJR Am J Roentgenol 2005;184:1103-1110   DOI   ScienceOn
24 Li T, Wang L, Yu HH, Sun HC, Qin LX, Ye QH, et al. Hepatic angiomyolipoma: a retrospective study of 25 cases. Surg Today 2008;38:529-535   DOI   ScienceOn
25 Hamm B, Staks T, Taupitz M. SHU 555A: a new superparamagnetic iron oxide contrast agent for magnetic resonance imaging. Invest Radiol 1994;29 Suppl 2:S87-S89   DOI
26 Reimer P, Rummeny EJ, Daldrup HE, Balzer T, Tombach B, Berns T, et al. Clinical results with resovist: a phase 2 clinical trial. Radiology 1995;195:489-496   DOI
27 Jeon TY, Kim SH, Lim HK, Lee WJ. Assessment of triple-phase CT findings for the differentiation of fat-deficient hepatic angiomyolipoma from hepatocellular carcinoma in non-cirrhotic liver. Eur J Radiol 2010;73:601-606   DOI   ScienceOn
28 Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578   DOI   ScienceOn
29 Nonomura A, Mizukami Y, Kadoya M. Angiomyolipoma of the liver: a collective review. J Gastroenterol 1994;29:95-105   DOI   ScienceOn
30 Yang CY, Ho MC, Jeng YM, Hu RH, Wu YM, Lee PH. Management of hepatic angiomyolipoma. J Gastrointest Surg 2007;11:452-457   DOI   ScienceOn
31 Zeng JP, Dong JH, Zhang WZ, Wang J, Pang XP. Hepatic Angiomyolipoma: a clinical experience in diagnosis and treatment. Dig Dis Sci Forthcoming 2010